Goldman Sachs Downgrades Atara Biotherapeutics (ATRA) to Sell

September 15, 2016 6:53 AM EDT
Get Alerts ATRA Hot Sheet
Price: $14.70 +5.00%

Rating Summary:
    4 Buy, 0 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade ATRA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Goldman Sachs downgraded Atara Biotherapeutics (NASDAQ: ATRA) from Neutral to Sell with a price target of $16.00 (from $23.00).

For an analyst ratings summary and ratings history on Atara Biotherapeutics click here. For more ratings news on Atara Biotherapeutics click here.

Shares of Atara Biotherapeutics closed at $21.33 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Downgrades, Hot Downgrades

Related Entities

Goldman Sachs

Add Your Comment